Professor James P. O'Gara completed his PhD in Microbiology at the University of Galway under the supervision of Professor L. Kieran Dunican, investigating the genetic basis of tryptophan overproduction in Corynebacterium glutamicum. He subsequently undertook postdoctoral training in two internationally recognised laboratories. At the University of Texas Medical School, Houston, in the laboratory of Professor Samuel Kaplan, he discovered a novel relationship between electron transport chain redox carriers and transcriptional regulation of photosynthesis gene expression, together with a new mechanism of tellurite resistance in Rhodobacter sphaeroides. Returning to Ireland in 1997, he joined the laboratory of Professor Charles J. Dorman at Trinity College Dublin, where he demonstrated how fimB promoter-driven transcription across the fim switch regulates phase-variable expression of type 1 fimbriae in Escherichia coli.

In 1999, Professor O'Gara was appointed Lecturer in Molecular Microbiology at the Royal College of Surgeons in Ireland, where he established an independent research programme investigating the molecular basis of virulence, biofilm formation and antimicrobial resistance in Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA). He was promoted to Senior Lecturer in 2003 before joining University College Dublin as Senior Lecturer in Microbiology in 2005. During his time at UCD, he served as Head of Graduate Studies in the School of Biomolecular and Biomedical Science and was a Conway Fellow from 2007 to 2012. He returned to the University of Galway in 2012 as Professor of Infectious Disease Microbiology, serving as Head of Microbiology (2013–2016) and as an elected member of the University's Governing Authority (2021–2025).
His research focuses on understanding the molecular and metabolic mechanisms underlying antimicrobial resistance, chronic staphylococcal infections and biofilm biology, with the objective of identifying new therapeutic strategies to combat antibiotic-resistant infections. His laboratory combines fundamental microbiology with translational research to discover new antimicrobial targets and improve the effectiveness of existing antibiotics against MRSA and other clinically important pathogens.

Professor O'Gara has made several influential contributions to the field of staphylococcal infection biology. These include the discovery of IcaR, the principal transcriptional regulator of staphylococcal biofilm production; the identification of multiple previously unrecognised mechanisms of biofilm formation mediated by fibronectin-binding proteins, the major autolysin and coagulase; the demonstration of fundamental links between methicillin resistance, biofilm formation and virulence; the development of novel therapeutic strategies for chronic MRSA infections, including β-lactam/nucleoside combination therapies; and the discovery of new metabolic targets that enhance β-lactam susceptibility, including alanine transport systems and succinyl-CoA synthetase-mediated regulation of lysine succinylation in the proteome.

His research has attracted sustained competitive funding from the Health Research Board, Research Ireland, the Irish Research Council and the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR). He has supervised numerous doctoral students and postdoctoral researchers who have progressed to successful careers in academia, healthcare and industry. He is currently an Editor for mSphere and the Journal of Medical Microbiology, and serves on major international funding panels and research evaluation committees, including the European Commission, UK Research and Innovation, the Polish National Science Centre and other leading international funding agencies.

Professor O'Gara was awarded the Doctor of Science (DSc) degree by the National University of Ireland in 2018 and was elected a Member of the Royal Irish Academy (MRIA) in 2022.

Overcoming antimicrobial resistance (AMR) in MRSA and other AMR pathogens. More than 25,000 people die because of AMR infections in the EU each year. The global number of deaths may be as high as 700,000. In the United States, there are more than 80,000 invasive MRSA infections every year responsible for 11,000 deaths (2013 Centre for Disease Control report). MRSA ranks as the 6th most common cause of bacterial infection and #1 in terms of mortality, despite most patients being treated with currently available anti-staphylococcal drugs. New drug development has not been able to keep pace with the emergence of so-called superbugs and the 2016 UK-government commissioned ONeill report warned that, without intervention, infections caused by AMR pathogens will be responsible for more deaths than cancer in 2050.

Penicillin-type antibiotics target the bacterial cell wall and remain among the safest and most effective antibiotics. However resistance is widespread. The O'Gara research group have identified new drug targets to increase the effectiveness of penicillin-type antibiotics, even against resistant bacteria like MRSA. The biological functions of these new drug targets and their mechanistic role in antibiotic resistance are currently being investigated using funding from Research Ireland (Frontiers for the Future Programme and IRC Postgraduate Scholarships), HRB (Investigator Led Project Grants) and JPIAMR (https://jpiamr.eu/projects/purify-amr/). These targets include alanine transporters required for MRSA cell wall integrity, succinyl-CoA synthetase which controls resistance to beta-lactam antibiotics via post-translational regulation of lysine succinylation in the proteome, and nucleoside transporters which control purine homeostasis required for high-level antibiotic resistance in MRSA. All of these new drug targets have the potential to impact antibiotic resistance in other AMR pathogens on the World Health Organisations list of global priority pathogens (the ESKAPE group: Enterococcus faecium, Staphylococcus aureus (MRSA), Klebsiella pneumoniae, Acinetobacter baumannii , Pseudomonas aeruginosa, and Enterobacter spp). Chronic biofilm-associated infections. The increased incidence of chronic biofilm-associated infections in healthcare systems has serious consequences in patient morbidity, mortality and treatment costs. Hospital-acquired infections are the 4th leading cause of disease and 70% are associated with medical devices. Implants are highly susceptible to the formation of biofilm, making bacteria resistant to the immune system and antibiotics. Biofilms are also involved in diabetic foot infections (DFIs), which area major complication of diabetes, with peripheral neuropathy often contributing to delayed diagnosis of these chronic infections. Biofilms are enriched with highly antibiotic-tolerant persister cells frequently rendering antibiotic treatment ineffective, which has major consequences for the patient, as well as placing an enormous economic burden on healthcare systems.

Media/Press Releases:

The Conversation - Antibiotic resistance

17th January 2023. New method to treat superbug infections

Breakthrough in treating MRSA infections

American Society for Microbiology: This Week in Microbiology podcast Dec 29th 2022.

29th June 2021. Galway scientists discover potential new method to treat superbug infections

15th November 2016. RTE news

9th July 2015. Breaking up MRSA - new discovery could reduce device-related infections in hospitals.

Professor O'Gara has taught microbiology across the undergraduate curricula of the Royal College of Surgeons in Ireland, University College Dublin and the University of Galway for more than 25 years, delivering modules from first year through to final year BSc (Hons). His teaching philosophy is to introduce students to fundamental concepts early in their university studies and progressively build on these foundations, ultimately probing primary research literature in the final undergraduate year. Professor O'Gara aims to demonstrate how fundamental microbiology underpins solutions to major clinical challenges such as antimicrobial resistance and chronic bacterial infection, enabling students to appreciate the impact of modern microbiological research. He has supervised numerous final year undergraduate research projects, alongside doctoral students and postdoctoral researchers

He coordinated first year Biology (BO101) for more than ten years and currently contributes to BO201 (Molecular and Cellular Biology), MI325 (Microbial Metabolism), MI326 (Microbial Metabolic and Molecular Systems), MI437 (Bacterial Pathogenesis) and MI4101 (Host–Microbe Interactions). Together, these modules span microbial physiology, metabolism, molecular microbiology, bacterial pathogenesis, host–pathogen interactions and antimicrobial resistance, reflecting his research interests.